Generali Investments Management Co LLC Buys Shares of 832 Cencora, Inc. $COR

Generali Investments Management Co LLC bought a new position in shares of Cencora, Inc. (NYSE:COR) during the second quarter, HoldingsChannel.com reports. The firm bought 832 shares of the company’s stock, valued at approximately $249,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC boosted its stake in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares during the last quarter. Costello Asset Management INC acquired a new stake in Cencora in the first quarter worth $28,000. University of Texas Texas AM Investment Management Co. bought a new position in shares of Cencora during the first quarter worth $39,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Cencora in the 2nd quarter valued at $61,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in shares of Cencora in the 2nd quarter valued at $61,000. 97.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on COR shares. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Robert W. Baird lifted their price objective on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. TD Cowen boosted their price objective on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Evercore ISI set a $400.00 target price on shares of Cencora and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Wells Fargo & Company lifted their price target on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $371.09.

Cencora Trading Down 1.0%

NYSE:COR opened at $361.97 on Friday. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $369.00. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The business has a 50 day moving average price of $321.35 and a two-hundred day moving average price of $302.16. The company has a market cap of $70.18 billion, a P/E ratio of 37.24, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The company had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same period last year, the company earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be given a dividend of $0.60 per share. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s payout ratio is presently 30.19%.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. This represents a 11.84% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 41,544 shares of company stock valued at $12,230,941. Company insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.